Browse the evidence

Dual-agonists targeting GLP-1 and Glucagon receptors (e.g., Mazdutide, Survodutide) offer superior weight loss and metabolic improvements compared to GLP-1 monotherapies, though they carry a higher risk of gastrointestinal adverse events.

Mazdutide is a once-weekly injection targeting both GLP-1 and Glucagon receptors. In trials, a 9mg dose led to an 18.6% average body weight loss over 48 weeks, outperforming many single-hormone drugs. However, patients should be aware of a higher rate of gastrointestinal side effects compared to some GLP-1 monotherapies, which may lead to discontinuation.

GLP-1 receptor agonists (GLP-1RAs) treat obesity by activating central and peripheral GLP-1 receptors to increase satiety, delay gastric emptying, and modulate energy expenditure, resulting in significant weight loss.

GLP-1 receptor agonists are a class of medications that mimic a gut hormone to signal fullness to the brain and slow digestion. They are prescribed for obesity and type 2 diabetes. Common examples include Semaglutide (Ozempic/Wegovy) and Liraglutide (Saxenda). These drugs require a prescription and often involve starting at a low dose to manage side effects like nausea. They are part of a long-term management strategy for obesity, not a quick fix.

GLP-1 receptor agonists (GLP-1 RAs) are displacing bariatric surgery as the primary obesity treatment in the US, evidenced by a 1451% increase in GLP-1 RA use and a 65% decline in bariatric surgery procedures.

GLP-1 medications are becoming the dominant obesity treatment in the US, largely replacing bariatric surgery in utilization trends. However, surgery remains a crucial option for severe obesity due to its durability, especially if GLP-1 medications are discontinued. Patients should discuss long-term adherence and potential side effects with their providers.

Tirzepatide significantly reduces the apnea-hypopnea index (AHI) and body weight in patients with moderate to severe obstructive sleep apnea (OSA) and obesity, regardless of whether they are using positive airway pressure (PAP) therapy.

If you have moderate to severe sleep apnea and obesity, Tirzepatide is a newly FDA-approved treatment that significantly reduces breathing interruptions during sleep and leads to substantial weight loss (18-20%). It works not just by shrinking fat around the airway, but also by reducing inflammation and affecting brain signals related to sleep. You can use it alone or alongside your CPAP machine. Because rapid weight loss can affect muscle, you should combine this medication with strength training and nutritional counseling.

GLP-1 receptor agonists (specifically Liraglutide) improve OSA outcomes when used in combination with CPAP, but CPAP alone is superior to Liraglutide monotherapy for reducing cardiovascular inflammation and plaque volume.

If you have severe sleep apnea and diabetes, adding Liraglutide to your CPAP therapy can further reduce breathing interruptions compared to using Liraglutide alone. However, CPAP is still necessary for protecting your heart and reducing arterial plaque, as Liraglutide alone does not provide this specific cardiovascular benefit. If you struggle with CPAP, discuss combination strategies with your doctor.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates rapidly increasing real-world utilization as both a glucose-lowering medication and an anti-obesity medication in patients with chronic kidney disease (CKD), with initiators showing high rates of obesity and morbid obesity.

For patients with CKD, tirzepatide is increasingly being used to manage both blood sugar and weight. Real-world data indicates that doctors are prescribing it more frequently, especially for those with obesity. While clinical trials have limited CKD representation, real-world usage is high and growing.

At higher doses (30% of energy), whey protein elicits a significantly greater insulinogenic response than soy protein, whereas at lower doses (15% of energy), both proteins produce similar insulin responses and have no differential effect on plasma glucose.

If you are healthy and normal weight, you can use either whey or soy protein for post-workout or meal supplementation without worrying about blood sugar spikes. At moderate amounts (around 15g protein), they behave the same. If you consume larger amounts (30g+), whey will trigger a higher insulin response than soy, but this did not negatively impact blood glucose levels in this study. For Asian Indians at higher risk for Type 2 Diabetes, moderate doses of either protein are equally effective for glucose homeostasis.

Long-term maintenance of cardiorespiratory fitness (CRF) improves insulin sensitivity in men with visceral obesity, even when visceral adipose tissue (VAT) rebounds.

Focus on maintaining your aerobic fitness (cardiorespiratory fitness) rather than obsessing over small fluctuations in body fat. If you maintain your fitness level, your body's ability to handle insulin remains high, even if you regain some visceral fat. Prioritize consistent physical activity over strict weight maintenance.

Reductions in intramuscular fat (specifically core and psoas low-attenuation muscle area) are associated with improved insulin resistance, independent of visceral fat changes.

Exercise helps reduce fat stored within muscles (intramuscular fat), which directly improves how your body uses insulin. This benefit occurs even if you don't lose all your belly fat.

Carbohydrate-restricted diets facilitate greater fat loss and weight loss maintenance in individuals with high insulin secretion or insulin resistance compared to low-fat diets, primarily by reducing hunger and preserving energy expenditure.

If you struggle with weight loss despite eating less, you may have high insulin levels. Try reducing carbohydrates (especially refined grains and sugars) without strictly counting calories. This approach may help control hunger and preserve energy expenditure, making it easier to lose fat and keep it off, especially if you have insulin resistance or type 2 diabetes.

Health and wellness coaching (HWC) interventions for obesity and Type 2 Diabetes (T2D) demonstrate beneficial clinical findings, but current randomized controlled trials (RCTs) exhibit moderate design quality (average 56.7% score), with T2D studies showing significantly better intervention design fidelity than obesity studies.

Health coaching works for obesity and diabetes, but the quality of the coaching matters more than just the number of sessions. Look for coaches who are certified (NBHWC) and use structured behavior change strategies. For obesity, ensure the program is long-term (over 4 months) and includes frequent sessions, as these studies showed lower design quality and potentially less effective delivery compared to diabetes programs.

Sustained moderate-intensity exercise (approx. 2000 kcal/week) prevents weight gain in young overweight women but produces significant fat loss in young overweight men, independent of dietary changes.

If you are a young overweight man, doing ~45 minutes of moderate exercise (where you can talk but not sing) 5 days a week will likely help you lose fat, even if you don't change your diet. If you are a young overweight woman, the same routine will likely stop you from gaining weight, which is a significant health benefit compared to doing nothing, even if the scale doesn't drop.

Noninvasive tests (FIB-4, ELF, MRE) are recommended for screening and risk stratification of MASLD, with FIB-4 as the first-line assessment due to its simplicity and cost-effectiveness.

If you have metabolic risk factors like obesity or type 2 diabetes, ask your doctor for a FIB-4 score. It is a simple, low-cost calculation using age, AST, ALT, and platelet count that helps identify liver fibrosis risk early.

Endoscopic bariatric therapies (EBMTs), including intragastric balloons and endoscopic sleeve gastroplasty, provide significant weight loss and metabolic improvements as minimally invasive alternatives to surgery, though they are associated with specific adverse events and potential weight regain.

Endoscopic bariatric therapies are a viable, minimally invasive option for weight loss, particularly for those who cannot or will not undergo surgery. Procedures like intragastric balloons and endoscopic sleeve gastroplasty can achieve significant weight loss (25-60% excess weight loss) when combined with lifestyle changes. However, they are not risk-free, with potential side effects ranging from nausea to rare serious complications. Patients should discuss their BMI, health status, and preference for invasiveness with a specialist to determine if an EBMT is appropriate, keeping in mind that some devices are temporary and may require combination with medication or surgery for long-term success.

GLP-1 receptor agonist therapy induces lean mass loss proportional to fat loss (approx. 25% of total weight loss), which is a physiological response to caloric restriction rather than a unique pathological catabolic effect of the drug.

If you are taking a GLP-1 drug like Semaglutide, expect to lose about 25% of your total weight as muscle. This is normal and similar to losing weight through diet alone. To protect your muscle, prioritize resistance training and eat 1.2-1.6g of protein per kg of body weight daily.

Increasing primary care provider (PCP) referral rates for weight loss surgery (WLS) significantly increases the volume of WLS procedures performed, with simulated interventions predicting up to a 24.1% increase in surgeries over 3 years.

If you are eligible for weight loss surgery, your primary care doctor's willingness to refer you is the biggest hurdle. This study suggests that simply encouraging your PCP to refer you to a specialist (endocrinologist or surgeon) significantly increases your chances of eventually having the surgery. If your PCP is hesitant, ask for a referral to a subspecialty obesity clinic, as this is a common stepping stone to surgery.

Preservation of skeletal muscle mass is a critical consideration in obesity treatment with second-generation medications, and new drugs (e.g., bimagrumab) are being developed to block muscle loss.

When you lose weight, you might lose some muscle. This is a concern, especially for older adults. New treatments are being developed to help preserve muscle mass while you lose fat. Talk to your doctor about strategies to maintain muscle strength during weight loss.

Dual GLP-1/GIP receptor agonism (e.g., tirzepatide) produces synergistic body weight loss compared to selective GLP-1 receptor agonists, a mechanism dependent on the interaction of signals in neurotensin-expressing neurons (Nts CeA) within the central amygdala.

Dual GLP-1/GIP medications (like tirzepatide) are more effective for weight loss than GLP-1-only drugs because they activate a specific brain pathway (neurotensin neurons in the central amygdala) that GLP-1 drugs alone do not fully engage. This biological synergy is the reason for their superior efficacy, not just better stomach tolerance.

Weekly subcutaneous semaglutide (2.4 mg) significantly improves functional capacity and reduces heart failure hospitalizations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction (HFpEF) and obesity, ask your doctor about weekly semaglutide injections (2.4 mg). This treatment has been shown to significantly improve your ability to perform daily activities, reduce your body weight, and lower your risk of being hospitalized for heart failure.

Semaglutide 2.4 mg administered once weekly for 68 weeks significantly improves health-related quality of life (HRQoL) utility scores compared to placebo in adults with overweight or obesity.

If you are an adult with overweight or obesity, taking 2.4 mg of semaglutide once weekly for about 16 months, alongside diet and exercise changes, is likely to significantly improve your daily health quality of life compared to placebo. This benefit is particularly pronounced if you have a higher BMI (over 40) or specific conditions like knee osteoarthritis or sleep apnea.

Waist circumference (WC) is a critical, 'vital' parameter for assessing cardiovascular risk in obesity, providing prognostic information that BMI alone fails to capture, particularly regarding visceral adipose tissue (VAT).

Ask your doctor to measure your waist circumference at every visit. It is a key indicator of heart disease risk that weight alone cannot show, especially if you have a 'normal' weight but carry fat around your midsection.

SGLT2 inhibitors reduce body weight and blood pressure, contributing to their overall benefit in CRM syndrome.

SGLT2 inhibitors typically lead to a modest weight loss of 1.5-3 kg over 1-2 years, which is a beneficial side effect for managing metabolic syndrome.

Bodybuilders primarily rely on fitness coaches and registered dietitians for information regarding dietary supplements, rather than independent medical advice or rigorous scientific literature.

When choosing supplements, prioritize advice from registered dietitians or nutritionists over fitness coaches, as coaches may lack specific nutritional expertise. This reduces the risk of misinformation and adverse effects.

The most commonly consumed dietary supplements among bodybuilders are Vitamin C, Vitamin D, and Whey Protein.

If you are a bodybuilder, you are likely taking Vitamin C, Vitamin D, and Whey Protein. Ensure your dosage of these is appropriate for your body weight and health status, and do not exceed recommended daily allowances without medical supervision.